Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
2.170
+0.070 (3.33%)
May 7, 2025, 4:00 PM - Market closed

Larimar Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Selling, General & Admin
18.9518.1114.4912.2812.0711.4
Upgrade
Research & Development
86.3972.7827.2724.2538.431.41
Upgrade
Operating Expenses
105.3490.8941.7636.5350.4742.8
Upgrade
Operating Income
-105.34-90.89-41.76-36.53-50.47-42.8
Upgrade
Other Non Operating Income (Expenses)
10.1110.294.811.17-0.170.32
Upgrade
Pretax Income
-95.23-80.6-36.95-35.36-50.64-42.48
Upgrade
Net Income
-95.23-80.6-36.95-35.36-50.64-42.48
Upgrade
Net Income to Common
-95.23-80.6-36.95-35.36-50.64-42.48
Upgrade
Shares Outstanding (Basic)
646144261712
Upgrade
Shares Outstanding (Diluted)
646144261712
Upgrade
Shares Change (YoY)
37.88%39.53%70.42%50.09%44.44%95.09%
Upgrade
EPS (Basic)
-1.49-1.32-0.84-1.37-2.95-3.57
Upgrade
EPS (Diluted)
-1.49-1.32-0.84-1.37-2.95-3.57
Upgrade
Free Cash Flow
-87.45-71.28-33.62-27.67-42.44-42.26
Upgrade
Free Cash Flow Per Share
-1.37-1.16-0.77-1.07-2.47-3.56
Upgrade
EBITDA
-105.02-90.57-41.45-36.21-50.14-42.65
Upgrade
D&A For EBITDA
0.330.320.310.320.330.16
Upgrade
EBIT
-105.34-90.89-41.76-36.53-50.47-42.8
Upgrade
Updated Mar 24, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q